Plaque Psoriasis Overview

Save information for later
Sign Up

Learn About Plaque Psoriasis

What is the definition of Plaque Psoriasis?
Plaque psoriasis is the most common form of psoriasis. Psoriasis is an autoimmune skin disorder that affects the growth rate of skin cells. Plaque psoriasis causes raised, reddened dry skin patches with silvery scales that appear on the scalp, elbows, knees, trunk and back.
What are the symptoms of Plaque Psoriasis?
Plaque psoriasis appears in cycles, with periods of remission followed by flare-ups that can last from weeks to months. Symptoms of plaque psoriasis during flare-ups can include reddened, dry skin patches covered in thick silvery scales, usually on the elbows, arms, knees, abdomen, and back, that may cause itching, burning, or bleeding. The sizes of the psoriasis plaques can range from small spots to covering large areas of the body. Nearly half of patients with psoriasis also have abnormal, thickened nails that are pitted or ridged. Psoriasis can also affect the mouth or genitals.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Plaque Psoriasis?
There is currently no cure for plaque psoriasis. Treatments for plaque psoriasis include topical therapy, such as corticosteroids, Vitamin D analogues, retinoids, calcineurin inhibitors, salicylic acid, coal tar, Goeckerman therapy, and anthralin; light therapy; other oral or injected medications; biologics; and alternative therapies.
Who are the top Plaque Psoriasis Local Doctors?
Bruce E. Strober
Elite in Plaque Psoriasis
Dr. Bruce E. Strober
Dermatology
Elite in Plaque Psoriasis
Dr. Bruce E. Strober
Dermatology

Central Connecticut Dermatology PLLC

1 Willowbrook Rd, Suite 2, 
Cromwell, CT 
860-322-2222
Languages Spoken:
English
See accepted insurances

Bruce Strober is a Dermatologist in Cromwell, Connecticut. Dr. Strober is rated as an Elite provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Psoriasis, Plaque Psoriasis, Pustular Psoriasis, and Generalized Pustular Psoriasis (GPP).

Andrew Blauvelt
Elite in Plaque Psoriasis
Dr. Andrew Blauvelt
Dermatology
Elite in Plaque Psoriasis
Dr. Andrew Blauvelt
Dermatology
9495 Sw Locust Street, Suite A, 
Portland, OR 
503-445-2200
Languages Spoken:
English
See accepted insurances

Andrew Blauvelt is a Dermatologist in Portland, Oregon. Dr. Blauvelt is rated as an Elite provider by MediFind in the treatment of Plaque Psoriasis. His top areas of expertise are Plaque Psoriasis, Psoriasis, Atopic Dermatitis, and Actinic Keratosis.

 
 
 
 
Learn about our expert tiers
Learn More
Kristian V. Reich
Elite in Plaque Psoriasis
Kristian V. Reich
Elite in Plaque Psoriasis
Kristian V. Reich
Hamburg, HH, DE 

Kristian Reich practices in Hamburg, Germany. Reich is rated as an Elite expert by MediFind in the treatment of Plaque Psoriasis. Their top areas of expertise are Psoriasis, Plaque Psoriasis, Atopic Dermatitis, and Psoriatic Arthritis.

View All Doctors
What are the latest Plaque Psoriasis Clinical Trials?
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Adolescent Participants (12 Years to Less Than 18 Years) With Moderate to Severe Plaque Psoriasis
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Other, Drug
Study Phase: Phase 3

Summary: The purpose of this study is to evaluate the efficacy, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

Match to trials
Find the right clinical trials for you in under a minute
Get started
Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis
Multicenter, Open Label or Double-Blind, Placebo-Controlled Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Pediatric Study Participants With Moderate to Severe Chronic Plaque Psoriasis
Who is this study for: Children with moderate to severe chronic plaque psoriasis
Enrollment Status: Recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Certolizumab pegol
Study Phase: Phase 3

Summary: The purpose of the study is to evaluate the pharmacokinetic (PK) of certolizumab pegol (CZP) in study participants aged 6 to 17 years with moderate to severe chronic plaque psoriasis (PSO) in order to support extrapolation of efficacy.

View All Clinical Trials